88 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Roche (Switzerland)CH2 papers
- Bayer (Germany)DE1 paper
- Biogen (United States)US1 paper
- Boehringer Ingelheim (Germany)DE1 paper
- Direktoratet for medisinske produkterNO1 paper
- Harvard UniversityUS1 paper
- McGill UniversityCA1 paper
- Medical University of ViennaAT1 paper
- Medizinische Hochschule HannoverDE1 paper
- Roche (Canada)CA1 paper
- Statistics AustriaAT1 paper
2 papers
stat.AP2022★ 88 cited
The use of external controls: To what extent can it currently be recommended?
Hans Ulrich Burger, Christoph Gerlinger, Chris Harbron +4
With more and better clinical data being captured outside of clinical studies and greater data sharing of clinical studies, external controls may become a more attractive alternati…
stat.ME2022★ 5 cited
Evaluating hybrid controls methodology in early-phase oncology trials: a simulation study based on the MORPHEUS-UC trial
Guanbo Wang, Melanie Poulin Costello, Herbert Pang +6
Phase Ib/II oncology trials, despite their small sample sizes, aim to provide information for optimal internal company decision-making concerning novel drug development. Hybrid con…